Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Appointments RAJ Devices May/June 2006

This article was originally published in RAJ Devices

Executive Summary

The US Food and Drug Administration (FDA) has announced the appointment of David Boyer as assistant commissioner for legislation. Mr Boyer will oversee the drafting of congressional testimony, respond to congressional enquiries and assist in the development of public health legislation. He will work closely with the Office of the Commissioner, as well as the six FDA centres. Mr Boyer has previously held senior positions at the Department of Health and Human Services (HHS), most recently that of special assistant for oversight in the office of the Assistant Secretary for Legislation. He joins the FDA from this role. Previous jobs have included director of federal government relations for the Biotechnology Industry Organization. Mr Boyer replaces Patrick Ronan, who becomes the FDA's chief of staff.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC094262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel